Krogsgaard: This is why we chose Seattle
Novo Nordisk already has a solid pipeline of obesity drugs, but the launch of a new research center in Seattle should further accelerate early stage R&D in the field - and there is a very clear reason the US city was chosen as the site, says the group's CSO.
BY STEFAN SINGH KAILAY
There is good obesity research being conducted in Denmark, and there is good obesity research being conducted in Cambridge, UK, for that matter, but there is a veritable hot spot for this branch of academic research in Seattle.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novo’s unit closure leads to 133 lay-offs
For abonnenter
Novo examines once-weekly insulin
For abonnenter
